---
layout: default
title: Tetrabenazine
description: "Tetrabenazine çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 167
evidence_level: L5
indication_count: 10
---

# Tetrabenazine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Tetrabenazine è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Tetrabenazine å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Tetrabenazineï¼ˆæ­¢è¹ˆéŒ ï¼‰æ˜¯ VMAT2 æŠ‘åˆ¶åŠ‘ç”¨æ–¼äº¨ä¸é “èˆè¹ˆç—‡ï¼ŒTxGNN é æ¸¬å…¶å°å¤šå›Šæ€§è…ç—…ç­‰å…·æ½›åŠ›ï¼Œä½†ç›®å‰åƒ…æœ‰å‰è‡¨åºŠè­‰æ“šã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Tetrabenazine |
| DrugBank ID | DB04844 |
| å°ç£å•†å“å | æ­¢è¹ˆéŒ  12.5 æ¯«å…‹ã€æ­¢è¹ˆéŒ  25 æ¯«å…‹ï¼ˆXenazineï¼‰ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | äº¨ä¸é “èˆè¹ˆç—‡ä¹‹èˆè¹ˆé‹å‹•ç—‡ç‹€ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | polycystic kidney disease 3 with or without polycystic liver diseaseã€renal-hepatic-pancreatic dysplasiaã€Joubert syndrome with renal defectã€karyomegalic interstitial nephritisã€thoracic malformationã€polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposisã€acute intermittent porphyriaã€adult familial nephronophthisis-spastic quadriparesia syndromeã€atypical glycine encephalopathyã€congenital disorder of glycosylation with defective fucosylation |
| æœ€é«˜è­‰æ“šç­‰ç´š | **L4**ï¼ˆå‰è‡¨åºŠè­‰æ“šï¼‰ |
| TxGNN åˆ†æ•¸ | 0.756ï¼ˆå¤šå›Šæ€§è…ç—…ï¼‰ |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†

### ä½œç”¨æ©Ÿè½‰æ”¯æŒ

Tetrabenazine é€éå¯é€†æ€§æŠ‘åˆ¶å›Šæ³¡å–®èƒºè½‰é‹è›‹ç™½ 2ï¼ˆVMAT2ï¼‰ï¼Œæ¸›å°‘å¤šå·´èƒºã€è¡€æ¸…ç´ å’Œæ­£è…ä¸Šè…ºç´ åœ¨ç¥ç¶“æœ«æ¢¢çš„å„²å­˜å’Œé‡‹æ”¾ï¼Œå¾è€Œæ¸›å°‘éåº¦é‹å‹•ç—‡ç‹€ã€‚

### é æ¸¬é©æ‡‰ç—‡åˆ†æ

1. **å¤šå›Šæ€§è…ç—…ç¬¬ 3 å‹ï¼ˆPKD3ï¼‰**
   - TxGNN åˆ†æ•¸ï¼š0.756
   - æ©Ÿè½‰é—œè¯ï¼šé–“æ¥ï¼Œå¯èƒ½èˆ‡ cAMP ä¿¡è™Ÿé€šè·¯æœ‰é—œ
   - è­‰æ“šç­‰ç´šï¼šåƒ…æœ‰çŸ¥è­˜åœ–è­œé æ¸¬

2. **è…-è‚-èƒ°ç™¼è‚²ä¸å…¨**
   - TxGNN åˆ†æ•¸ï¼š0.712
   - æ©Ÿè½‰é—œè¯ä¸æ˜ç¢º
   - è­‰æ“šç­‰ç´šï¼šåƒ…é æ¸¬

3. **ä¹³ä¹™ä¼¯ç—‡å€™ç¾¤ï¼ˆJoubert syndromeï¼‰**
   - TxGNN åˆ†æ•¸ï¼š0.698
   - æ©Ÿè½‰é—œè¯ä¸æ˜ç¢º
   - è­‰æ“šç­‰ç´šï¼šåƒ…é æ¸¬

### æ©Ÿè½‰åˆ†æçš„æŒ‘æˆ°

TxGNN çš„é æ¸¬ä¸»è¦åŸºæ–¼çŸ¥è­˜åœ–è­œä¸­çš„é—œè¯æ€§ï¼Œè€Œéç›´æ¥çš„æ©Ÿè½‰è­‰æ“šã€‚Tetrabenazine ä½œç‚º VMAT2 æŠ‘åˆ¶åŠ‘ï¼Œå…¶åœ¨è…è‡Ÿç–¾ç—…ä¸­çš„æ½›åœ¨ä½œç”¨æ©Ÿè½‰ä¸æ˜ç¢ºï¼š

- å¯èƒ½çš„å‡èªªï¼šå–®èƒºé¡ç¥ç¶“å‚³å°ç‰©è³ªå°è…è‡Ÿå›Šè…«ç”Ÿé•·æœ‰å½±éŸ¿
- ç›®å‰ç„¡ç›´æ¥è­‰æ“šæ”¯æŒ

## è‡¨åºŠè©¦é©—è­‰æ“š

### é æ¸¬é©æ‡‰ç—‡ç›¸é—œè©¦é©—

**ç›®å‰ç„¡ç›¸é—œè‡¨åºŠè©¦é©—**

æœå°‹ ClinicalTrials.gov å’Œ ICTRP å‡æœªç™¼ç¾ Tetrabenazine ç”¨æ–¼ï¼š
- å¤šå›Šæ€§è…ç—…
- è…-è‚-èƒ°ç™¼è‚²ä¸å…¨
- ä¹³ä¹™ä¼¯ç—‡å€™ç¾¤

çš„ç›¸é—œè‡¨åºŠè©¦é©—ã€‚

### ç¾æœ‰é©æ‡‰ç—‡è©¦é©—ï¼ˆåƒè€ƒï¼‰

Tetrabenazine åœ¨äº¨ä¸é “èˆè¹ˆç—‡å’Œå…¶ä»–é‹å‹•éšœç¤™æœ‰å……åˆ†çš„è‡¨åºŠè©¦é©—è­‰æ“šã€‚

## æ–‡ç»è­‰æ“š

### é æ¸¬é©æ‡‰ç—‡ç›¸é—œæ–‡ç»

**æœå°‹çµæœï¼šæœªç™¼ç¾ç›´æ¥ç›¸é—œæ–‡ç»**

åœ¨ PubMed ä¸­æœå°‹ Tetrabenazine èˆ‡å¤šå›Šæ€§è…ç—…ã€è…ç™¼è‚²ä¸å…¨ã€ä¹³ä¹™ä¼¯ç—‡å€™ç¾¤çš„çµ„åˆï¼Œå‡æœªç™¼ç¾ç›¸é—œç ”ç©¶ã€‚

### å¯èƒ½çš„é–“æ¥é—œè¯

éƒ¨åˆ†æ–‡ç»æ¢è¨å–®èƒºé¡ç¥ç¶“å‚³å°ç‰©è³ªåœ¨è…è‡Ÿç”Ÿç†çš„è§’è‰²ï¼Œä½†æœªç›´æ¥æ¶‰åŠ Tetrabenazineï¼š
- å¤šå·´èƒºå—é«”åœ¨è…è‡Ÿæœ‰è¡¨é”
- è¡€æ¸…ç´ å¯èƒ½å½±éŸ¿è…è¡€æµ

é€™äº›é–“æ¥é—œè¯ä¸è¶³ä»¥æ”¯æŒè‡¨åºŠæ‡‰ç”¨ã€‚

## å°ç£ä¸Šå¸‚è³‡è¨Š

### å·²æ ¸å‡†ç”¢å“

| è¨±å¯è­‰è™Ÿ | å•†å“å | åŠ‘å‹ | å«é‡ |
|----------|--------|------|------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026234è™Ÿ | æ­¢è¹ˆéŒ  12.5 æ¯«å…‹ | éŒ åŠ‘ | 12.5 mg |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026235è™Ÿ | æ­¢è¹ˆéŒ  25 æ¯«å…‹ | éŒ åŠ‘ | 25 mg |

### å¥ä¿çµ¦ä»˜ç‹€æ…‹

**çµ¦ä»˜æ¢ä»¶**ï¼š
- é™ç”¨æ–¼äº¨ä¸é “èˆè¹ˆç—‡ä¹‹èˆè¹ˆé‹å‹•ç—‡ç‹€
- éœ€ç”±ç¥ç¶“ç§‘å°ˆç§‘é†«å¸«è™•æ–¹
- éœ€äº‹å‰å¯©æŸ¥

## å®‰å…¨æ€§è€ƒé‡

### è—¥ç‰©äº¤äº’ä½œç”¨ï¼ˆé‡è¦ï¼‰

Tetrabenazine æœ‰å¤šé …é‡è¦è—¥ç‰©äº¤äº’ä½œç”¨ï¼š

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡ç¨‹åº¦ | æ©Ÿè½‰/èªªæ˜ |
|--------------|----------|-----------|
| **Bupropion** | **é‡åº¦** | é™ä½ç™²ç™‡é–¾å€¼ |
| **Metoclopramide** | **é‡åº¦** | å¢åŠ éŒé«”å¤–å¾‘å‰¯ä½œç”¨ |
| **Cisapride** | **é‡åº¦** | QT å»¶é•·é¢¨éšª |
| **Papaverine** | **é‡åº¦** | å¿ƒå¾‹ä¸æ•´é¢¨éšª |
| **Promethazine** | **é‡åº¦** | å¢åŠ  CNS æŠ‘åˆ¶ |
| **Methylene blue** | **é‡åº¦** | è¡€æ¸…ç´ ç—‡å€™ç¾¤é¢¨éšª |
| MAO æŠ‘åˆ¶åŠ‘ | é‡åº¦ | é«˜è¡€å£“å±è±¡ |
| Reserpine | é‡åº¦ | éåº¦å–®èƒºè€—ç«­ |
| æŠ—ç²¾ç¥ç—…è—¥ | ä¸­åº¦ | å¢åŠ  EPS é¢¨éšª |
| æŠ—æ†‚é¬±åŠ‘ | ä¸­åº¦ | æ†‚é¬±æƒ¡åŒ–é¢¨éšª |
| Levodopa | ä¸­åº¦ | æ‹®æŠ—ä½œç”¨ |

### ä¸»è¦ä¸è‰¯åæ‡‰

- **å¸¸è¦‹**ï¼šå—œç¡ã€ç–²å‹ã€å¸•é‡‘æ£®ç—‡ç‹€ã€å™å¿ƒ
- **è¼ƒå°‘è¦‹**ï¼šæ†‚é¬±ã€ç„¦æ…®ã€å¤±çœ ã€éœåä¸èƒ½
- **åš´é‡**ï¼š
  - **æ†‚é¬±èˆ‡è‡ªæ®ºé¢¨éšª**ï¼ˆé»‘æ¡†è­¦å‘Šï¼‰
  - æƒ¡æ€§ç¥ç¶“æŠ‘åˆ¶ç—‡å€™ç¾¤ï¼ˆNMSï¼‰
  - QT å»¶é•·

### é»‘æ¡†è­¦å‘Š

**æ†‚é¬±èˆ‡è‡ªæ®ºé¢¨éšª**ï¼š
- Tetrabenazine å¯èƒ½å°è‡´æˆ–æƒ¡åŒ–æ†‚é¬±ç—‡
- æ‚£è€…å¯èƒ½å‡ºç¾è‡ªæ®ºæ„å¿µ
- éœ€å¯†åˆ‡ç›£æ¸¬æƒ…ç·’è®ŠåŒ–
- æœ‰é‡åº¦æ†‚é¬±ç—‡ç—…å²è€…ç¦ç”¨

### ç‰¹æ®Šæ—ç¾¤æ³¨æ„äº‹é …

- **è‚åŠŸèƒ½ä¸å…¨**ï¼šéœ€æ¸›é‡
- **CYP2D6 ä»£è¬å·®è€…**ï¼šéœ€æ¸›é‡
- **è€å¹´äºº**ï¼šè¬¹æ…ä½¿ç”¨ï¼Œå‰¯ä½œç”¨é¢¨éšªå¢åŠ 
- **æ‡·å­•**ï¼šCategory C

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šAlcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and...
- å»ºè­°ï¼šPatients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities r...


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Deglutition Disorders** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**Hyperprolactinemia** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šTetrabenazine can elevate serum prolactin concentrations...

**ä½è¡€å£“** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€å£“ã€‚

**Arrhythmias, Cardiac** ğŸŸ¢ Minor
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå¿ƒå¾‹ä¸æ•´ã€‚

**Depressive Disorder** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚

**Hepatic Insufficiency** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚

**Huntington Disease** ğŸŸ¢ Minor
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬å¯ä¿¡åº¦è©•ä¼°

| é æ¸¬é©æ‡‰ç—‡ | è­‰æ“šç­‰ç´š | å¯ä¿¡åº¦ | å»ºè­° |
|------------|----------|--------|------|
| å¤šå›Šæ€§è…ç—… | L5 | ä½ | ä¸å»ºè­°è‡¨åºŠæ‡‰ç”¨ |
| è…-è‚-èƒ°ç™¼è‚²ä¸å…¨ | L5 | ä½ | ä¸å»ºè­°è‡¨åºŠæ‡‰ç”¨ |
| ä¹³ä¹™ä¼¯ç—‡å€™ç¾¤ | L5 | ä½ | ä¸å»ºè­°è‡¨åºŠæ‡‰ç”¨ |

### è‡¨åºŠæ‡‰ç”¨å»ºè­°

**ä¸å»ºè­°å°‡ Tetrabenazine ç”¨æ–¼é æ¸¬çš„æ–°é©æ‡‰ç—‡**

ç†ç”±ï¼š
1. ç„¡è‡¨åºŠè©¦é©—è­‰æ“š
2. ç„¡æ–‡ç»æ”¯æŒ
3. æ©Ÿè½‰é—œè¯ä¸æ˜ç¢º
4. è—¥ç‰©å®‰å…¨æ€§é¢¨éšªé«˜ï¼ˆé»‘æ¡†è­¦å‘Šã€å¤šé‡è—¥ç‰©äº¤äº’ä½œç”¨ï¼‰
5. é æ¸¬çš„ç–¾ç—…å¤šç‚ºç½•è¦‹éºå‚³ç–¾ç—…ï¼Œéœ€è¬¹æ…è©•ä¼°é¢¨éšªæ•ˆç›Š

### ç ”ç©¶åƒ¹å€¼è©•ä¼°

é›–ç„¶ä¸å»ºè­°è‡¨åºŠæ‡‰ç”¨ï¼Œä½† TxGNN çš„é æ¸¬å¯èƒ½æ­ç¤ºä¸€äº›æ½›åœ¨çš„ç”Ÿç‰©å­¸é—œè¯ï¼š

1. **åŸºç¤ç ”ç©¶åƒ¹å€¼**ï¼šæ¢è¨å–®èƒºé¡ç¥ç¶“å‚³å°ç‰©è³ªåœ¨å›Šè…«æ€§è…ç—…ä¸­çš„è§’è‰²
2. **æ©Ÿè½‰ç ”ç©¶**ï¼šVMAT2 æ˜¯å¦åœ¨è…è‡Ÿæœ‰è¡¨é”å’ŒåŠŸèƒ½
3. **å‹•ç‰©æ¨¡å‹é©—è­‰**ï¼šå¯åœ¨å¤šå›Šæ€§è…ç—…å‹•ç‰©æ¨¡å‹ä¸­è©•ä¼° Tetrabenazine çš„æ•ˆæœ

### å»ºè­°å¾ŒçºŒæ­¥é©Ÿ

1. **æ–‡ç»å›é¡§**ï¼šæ·±å…¥æœå°‹å–®èƒºé¡ç‰©è³ªèˆ‡å›Šè…«æ€§è…ç—…çš„é—œè¯
2. **å‰è‡¨åºŠç ”ç©¶**ï¼šè‹¥æœ‰èˆˆè¶£ï¼Œå¯åœ¨ç´°èƒæˆ–å‹•ç‰©æ¨¡å‹ä¸­é©—è­‰
3. **ä¸å»ºè­°ç›´æ¥é€²è¡Œè‡¨åºŠè©¦é©—**

---

*æœ¬ç­†è¨˜ç”± TxGNN é æ¸¬ç³»çµ±ç”¢ç”Ÿï¼Œåƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚*
*æ›´æ–°æ—¥æœŸï¼š2026-02-11*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Atracurium Besylate]({{ "/drugs/atracurium_besylate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Verteporfin]({{ "/drugs/verteporfin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Benzylpenicillin]({{ "/drugs/benzylpenicillin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Felodipine]({{ "/drugs/felodipine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Methionine]({{ "/drugs/methionine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Tetrabenazineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/tetrabenazine/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_tetrabenazine,
  title = {Tetrabenazineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/tetrabenazine/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
